Citation

Elzagallaai AA, Greff MJ, Rieder MJ. Clin. Pharmacol. Ther. 2017; 101(6): 725-735.

Affiliation

Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada.

Copyright

(Copyright © 2017, American Society for Clinical Pharmacology and Therapeutics, Publisher Nature Publishing Group)

DOI

10.1002/cpt.677

PMID

28295234

Abstract

Adverse drug reactions (ADRs) represent a major health problem worldwide with high morbidity and mortality rates. ADRs are classified into type A (augmented) and type B (bizarre) ADRs with the former group being more common and the later less common but often severe and clinically more problematic due to their unpredictable nature and occurrence at any dose. Pediatric populations are especially vulnerable to ADRs due to the lack of data for this age group from the drug development process and because of the wide use of Off-label and unlicensed use of drugs. Children are more prone to specific types of ADRs because of the level of maturity of body systems involved in absorption, metabolism, transportation and elimination of drugs. This state-of-the-are review provides an overview of definitions, classifications, epidemiology and pathophysiology of ADRs and discusses the available evidence for related risk factors and causes of ADRs in the pediatric population. This article is protected by copyright. All rights reserved.

© 2017 American Society for Clinical Pharmacology and Therapeutics.

Language: en

Keywords

Adverse drug reactions; children; drug allergy; drug hypersensitivity; idiosyncratic drug reactions; pediatric; side effects